Lascco
Company Team Projects Media Contact
 
     

 

CAL02 - A first-line life-saving drug

 

Results in patients with severe community-acquired pneumonia: The Lancet Infectious Diseases (in press).

 

Selected Publications

CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
Laterre PF et al. Lancet Infect Dis. 2019 May 2 (Online First)
.

One step closer to precision medicine for infectious diseases.
Pletz MW et al. Lancet Infect Dis. 2019 May 2 (Online First)
.

CAL02 liposomes and other anti-toxins: A new generation of anti-infectives.
Azeredo da Silveira S and Perez A. Clin Pulm Med 2018; 25(3):84-88
.

Liposomal therapy attenuates dermonecrosis induced by community-associated methicillin-resistant Staphilococcus aureus by targeting a-type phenol soluble modulins and a-hemolysin.
Wolfmeier H et al. EbioMedicine 2018; 33:211-217.

Clinical Streptococcus pneumoniae isolates induce differing CXCL8 responses from human nasopharyngeal epithelial cells which are reduced by liposomes.
Baumgartner D et al. BMC Microbiology, 2016; 16:154.

Precision medicine for the treatment of severe pneumonia in intensive care.
Rello J and Perez A. Expert Review of Respiratory Medicine 2016; 10(3):297-316.

Liposomes as novel anti-infectives targeting bacterial virulence factors?
Azeredo da Silveira S and Perez A. Expert Review of Anti-infective Therapy 2015; 13(5):531-3
.

Engineered liposomes sequester bacterial exotoxins and protec from severe invasive infections in mice.
Henry BD et al. Nature Biotechnology 2015; 33(1):81-8.

 

Lascco